Bristol Myers Squibb Tops Q4 Estimates


cafead

Administrator
Staff member
  • cafead   Feb 06, 2025 at 12:02: PM
via
  • Adjusted EPS of $1.67 beat expectations of $1.46.
  • Revenue rose to $12.3 billion, exceeding estimates of $11.57 billion.
  • The growth portfolio of drugs saw a 21% revenue increase, driven by Reblozyl, Breyanzi, and Camzyos.

article source